Clinical Trial Update: Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients [Phase 1]

View source ↗

Summary

A Phase Ib trial evaluating the KRAS G12C inhibitor adagrasib in KRAS G12C mutant metastatic pancreatic cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Adagrasib (adagrasib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Pancreatic Cancer | Phase 1 | Status: WITHDRAWN